- Home
- ACV vs FULC Comparison
ACV vs FULC Comparison
Compare ACV & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACV
- FULC
- Stock Information
- Founded
- ACV 2015
- FULC 2015
- Country
- ACV United States
- FULC United States
- Employees
- ACV N/A
- FULC N/A
- Industry
- ACV Finance/Investors Services
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- ACV Finance
- FULC Health Care
- Exchange
- ACV Nasdaq
- FULC Nasdaq
- Market Cap
- ACV 233.8M
- FULC 210.9M
- IPO Year
- ACV N/A
- FULC 2019
- Fundamental
- Price
- ACV $19.83
- FULC $3.01
- Analyst Decision
- ACV
- FULC Hold
- Analyst Count
- ACV 0
- FULC 8
- Target Price
- ACV N/A
- FULC $6.57
- AVG Volume (30 Days)
- ACV 38.8K
- FULC 465.5K
- Earning Date
- ACV 01-01-0001
- FULC 05-12-2025
- Dividend Yield
- ACV 9.20%
- FULC N/A
- EPS Growth
- ACV N/A
- FULC N/A
- EPS
- ACV N/A
- FULC N/A
- Revenue
- ACV N/A
- FULC $80,000,000.00
- Revenue This Year
- ACV N/A
- FULC N/A
- Revenue Next Year
- ACV N/A
- FULC N/A
- P/E Ratio
- ACV N/A
- FULC N/A
- Revenue Growth
- ACV N/A
- FULC 2752.05
- 52 Week Low
- ACV $16.82
- FULC $2.78
- 52 Week High
- ACV $23.74
- FULC $10.13
- Technical
- Relative Strength Index (RSI)
- ACV 31.15
- FULC 40.55
- Support Level
- ACV $20.20
- FULC $3.00
- Resistance Level
- ACV $20.99
- FULC $3.35
- Average True Range (ATR)
- ACV 0.44
- FULC 0.19
- MACD
- ACV 0.05
- FULC 0.03
- Stochastic Oscillator
- ACV 4.92
- FULC 40.71
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It seeks to achieve its investment objective by investing in a combination of convertible securities, debt and other income-producing instruments and common stocks and other equity securities.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.